Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amfetamine prodrug - Ensysce Biosciences

Next Previous
Drug Profile

Amfetamine prodrug - Ensysce Biosciences

Alternative Names: Abuse-resistant amphetamine; Amfetamine - PharmacoFore; Amphetamine prodrug; Dexamfetamine - Ensysce Biosciences; Dexamphetamine - Ensysce Biosciences; PF-08; PF-8001; PF-8026; PF8001 / PF8026; PFR 08001; PFR08026

Latest Information Update: 02 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 02 Jun 2026 Amfetamine prodrug (PF 8001/PF 8026) is still in preclinical trials for Attention-deficit hyperactivity disorder in USA (Ensysce Biosciences pipeline, June 2026)
  • 28 Oct 2024 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Controlled release)
  • 28 Oct 2024 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Immediate release)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top